Inmune Bio (INMB) AI Stock Analysis

• Market Cap: $48.65M
• Dividend Yield: N/A
• Average Volume (3M): 376.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: 19.05%
• EPS Growth: 2.01%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 26,585,258
• 10 Day Avg. Volume: 338,193
• 30 Day Avg. Volume: 376,837
• PEG Ratio: -0.08
• Price to Book (P/B): 2.90
• Price to Sales (P/S): 6652.75
• P/FCF Ratio: -2.79
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $8.00
• Price Target Upside: 316.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 52 Neutral
• Price Target: ―

Inmune Bio's overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

Positive Factors

Intellectual Property

Securing a favorable patentability opinion enhances INmune Bio's intellectual property portfolio, potentially providing market exclusivity until 2045. This strengthens the company's competitive position and supports long-term strategic growth in the biotechnology sector.

Pipeline Progress

The anticipated Phase 2 trial results for XPro in Alzheimer's disease could significantly enhance INmune Bio's market position in neurodegenerative therapies, demonstrating the company's innovative approach and potential to address unmet medical needs.

Strategic Partnerships

The license agreement for CORDStrom data with a leading hospital enhances INmune Bio's ability to commercialize its therapies in the US and Europe, potentially accelerating market entry and expanding revenue streams through strategic collaborations.

Negative Factors

Financial Performance

The sharp decline in revenue and ongoing losses highlight financial instability, which could hinder INmune Bio's ability to fund R&D and operational activities, impacting long-term growth and sustainability in the competitive biotech industry.

Cash Flow Challenges

Negative cash flows and increased cash burn indicate reliance on external funding, which can strain financial resources and limit operational flexibility, posing risks to INmune Bio's long-term financial health and ability to sustain its pipeline development.

Screening Failure Rate

The high screening failure rate in the Alzheimer's trial could delay clinical progress and increase costs, challenging INmune Bio's ability to efficiently advance its pipeline and achieve timely regulatory approvals, impacting strategic objectives.

Inmune Bio Business Overview & Revenue Model

Company Description

Inmune Bio, Inc. (INMB) is a biotechnology company focused on developing innovative therapies to modulate components of the immune system to treat cancer and neurodegenerative diseases. The company operates within the biotechnology and pharmaceutical sectors, leveraging its proprietary platforms to target innate immune cells. Core products in its pipeline include INKmune, which aims to enhance the ability of natural killer cells to attack cancer, and XPro1595, designed to inhibit neuroinflammation linked to Alzheimer's disease.

How the Company Makes Money

Inmune Bio primarily generates revenue through strategic partnerships, licensing agreements, and potential future sales of its proprietary therapies upon approval. The company may receive upfront payments, milestone payments, and royalties from its collaborative partners. Additionally, Inmune Bio could benefit from government grants and research funding to support its scientific advancements. As its therapies progress through clinical trials and obtain regulatory approvals, commercializing these treatments will be critical for driving significant revenue growth.

Inmune Bio Financial Statement Overview

Summary

Inmune Bio's financial performance is weak, with a sharp decline in revenue and persistent losses. Despite a relatively strong equity position and decreasing debt-to-equity ratio, the company's ongoing cash burn and negative cash flows highlight significant financial distress.

Income Statement

Inmune Bio has shown a significant decline in revenue, with a steep drop from $77.69 million in 2019 to $14,000 in 2024. The company consistently records negative net income and EBIT, highlighting ongoing unprofitability. Margins are severely negative, and the shrinking revenue base raises concerns about future growth prospects.

Balance Sheet

The company maintains a relatively strong equity position with a decreasing debt-to-equity ratio, indicating potential stability in its financial leverage. However, the overall reduction in total assets and equity suggests a diminishing scale of operations, which might affect future growth capabilities.

Cash Flow

Operating cash flows remain negative, reflecting ongoing operational challenges. There was a significant decrease in free cash flow over recent periods, indicating increased cash burn. Positive financing cash flows in some years suggest reliance on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	50.00K	14.00K	155.00K	374.00K	181.00K	11.00K
Gross Profit	50.00K	14.00K	155.00K	374.00K	181.00K	11.00K
EBITDA	-51.13M	-42.08M	-29.74M	-25.95M	-29.15M	-12.23M
Net Income	-49.89M	-42.08M	-30.01M	-27.30M	-30.34M	-12.10M
Balance Sheet
Total Assets	33.36M	39.56M	57.00M	81.80M	99.94M	40.66M
Cash, Cash Equivalents and Short-Term Investments	27.73M	20.92M	35.85M	52.15M	74.81M	21.97M
Total Debt	1.08M	384.00K	10.44M	15.31M	15.23M	160.16K
Total Liabilities	7.98M	7.46M	18.86M	21.69M	19.72M	1.90M
Stockholders Equity	25.38M	32.10M	38.14M	60.10M	80.22M	38.75M
Cash Flow
Free Cash Flow	-30.65M	-33.36M	-11.98M	-22.69M	-43.50M	-8.94M
Operating Cash Flow	-30.65M	-33.36M	-11.98M	-22.69M	-28.50M	-8.94M
Investing Cash Flow	-899.00K	0.00	0.00	0.00	-15.00M	0.00
Financing Cash Flow	25.47M	18.21M	-4.22M	729.00K	96.36M	23.89M

Inmune Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.92
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INMB, the sentiment is Negative. The current price of 1.92 is above the 20-day moving average (MA) of 1.88, below the 50-day MA of 1.96, and below the 200-day MA of 5.36, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.89 is Neutral, neither overbought nor oversold. The STOCH value of 26.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INMB.

Inmune Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INMB	―	$48.65M	―	-155.77%	―	19.05%	2.01%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KPTI	―	$50.29M	-0.40	―	―	-5.77%	-22.78%
VERU	―	$43.24M	―	-96.35%	―	-52.76%	43.40%
CUE	―	$53.75M	-1.27	-195.55%	―	-0.11%	43.47%
CELU	―	$55.25M	-0.65	-6367.24%	―	4.45%	45.19%

Inmune Bio Corporate Events

Inmune Bio Secures Favorable Patentability Opinion for CORDStrom™

On April 16, 2025, INmune Bio Inc. announced receiving a favorable patentability opinion from the United States Patent and Trademark Office for its CORDStrom™ platform, a next-generation mesenchymal stromal cell product. This development marks a significant milestone, potentially enhancing the company’s intellectual property exclusivity until 2045 and accelerating the U.S. national application process. The favorable opinion follows promising Phase 2 trial results, indicating CORDStrom™’s potential in reducing pain and improving skin conditions, which could unlock substantial therapeutic and commercial opportunities.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score reflects significant financial challenges, including declining revenue and ongoing losses. Technical indicators show potential downward momentum, while valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

Inmune Bio Presents Alzheimer’s Trial Data at Conference

On April 3, 2025, INmune Bio Inc. presented a poster at the International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, detailing the demographics and biomarker status of patients in their MINDFul Phase II trial for early Alzheimer’s disease. The trial, which completed enrollment in November 2024, aims to evaluate the cognitive benefits of XPro1595 in patients with biomarkers of immune dysfunction. Preliminary analyses indicate successful enrollment of a well-characterized cohort, with top-line results expected in June 2025, potentially impacting the company’s positioning in Alzheimer’s treatment development.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score reflects significant financial challenges, including declining revenue and ongoing losses. Technical indicators show potential downward momentum, while valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

INmune Bio Reports Promising Phase I/II Trial Results

INmune Bio Inc. has released preliminary results from a Phase I/II trial of its INKmune therapy, which targets metastatic, castration-resistant prostate cancer by activating NK cells. The trial, which began in March 2025, has shown promising safety and immunologic efficacy, with no serious adverse effects reported after 29 infusions across three dosage levels. The trial aims to determine the effective dose and assess both short- and long-term safety, as well as the therapy’s ability to control tumor burden. The results could enhance INmune Bio’s position in the cancer immunotherapy market and provide significant implications for stakeholders, particularly in terms of advancing cancer treatment options.

Inmune Bio Secures License Agreement for CORDStrom Data

On February 6, 2025, INmune Bio entered a license agreement with Great Ormond Street Hospital NHS Foundation Trust for exclusive commercial use of clinical trial data from the Mission EB study, which investigates CORDStrom’s efficacy in treating pediatric RDEB. This agreement allows INmune Bio to prepare applications for marketing authorization in the US and Europe. The company will provide CORDStrom to UK patients enrolled in ongoing studies and pay milestone fees upon receiving the first marketing authorization. Additionally, INmune Bio announced the termination of its Loan Agreement with Silicon Valley Bank without penalties. The Mission EB study demonstrated CORDStrom’s potential in treating RDEB, leading to plans for filing a Biologics License Application with the FDA and similar applications in Europe. CORDStrom has been granted Rare Pediatric Disease and Orphan Drug designations by the FDA, enhancing its market potential and support for further development.

Inmune Bio Completes Phase 2 Trial for CORDStrom

INmune Bio Inc. announced the completion of a Phase 2 clinical trial for its CORDStrom platform, designed to treat Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. The trial demonstrated that CORDStrom was safe, well-tolerated, and provided clinical benefit, particularly in alleviating itch, a significant problem for RDEB patients. The company is preparing to submit a Biologics License Application to the FDA by the end of 2025, aiming for potential approval and market launch in 2026, which could significantly impact their market positioning and offer a novel treatment option for this unmet medical need.